A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 and Nivolumab in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Life-Prolonging Therapies (PRIMETIME)

Trial Profile

A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 and Nivolumab in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Life-Prolonging Therapies (PRIMETIME)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs RRx 001 (Primary) ; Nivolumab
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Acronyms PRIMETIME
  • Sponsors EpicentRx
  • Most Recent Events

    • 02 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.
    • 02 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.
    • 02 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top